Universität zu Köln

Jeck, Julia ORCID: 0000-0002-4669-690X, Jakobs, Florian, Kron, Anna, Cornely, Oliver A. ORCID: 0000-0001-9599-3137 and Kron, Florian ORCID: 0000-0003-4907-7490 (2022). Retrospective modelling of hospital bed capacities associated with the administration of remdesivir during the first wave of COVID-19 in a German metropolitan city. J. Antimicrob. Chemother., 77 (3). S. 753 - 758. OXFORD: OXFORD UNIV PRESS. ISSN 1460-2091

Full text not available from this repository.

Abstract

Objectives Internationally, healthcare systems are confronted by an ever-increasing scarcity of medical resources due to the ongoing novel coronavirus disease 2019 (COVID-19) pandemic. The aim of this study was to investigate the impact of remdesivir on the demand of hospital bed capacities for hospitalized COVID-19 patients and to evaluate the potentially created capacities for treating additional COVID-19 patients or elective treatments at the hospital. Methods An epidemiological model was developed that utilized the population of Cologne (Germany) during the first COVID-19 wave (first hospitalized patient-30 September 2020) to compare two scenarios: no administration of remdesivir (A) and the administration of remdesivir according to the EMA label (B). The results of the Adaptive COVID-19 Treatment Trial were used to evaluate the potential impact of remdesivir on hospital capacity. Results With the first recorded patient on 2 March 2020, a total of 576 COVID-19 hospitalized patients were detected during the first wave in Cologne. Comparing both scenarios (A versus B) of the model, the administration of remdesivir increased the number of discharges from 259 to 293 (+5.8%) and fewer patients needed ICU admission [214 versus 178 (-6.3%)]. In addition, the model estimated 20 fewer deaths (scenario B). Based on a reduced length of stay, 31.4 hospital beds (57.0 versus 25.6) could have been freed by administering remdesivir to eligible patients. This would have allowed either the treatment of an additional 730 COVID-19 patients or 660 elective treatments. Conclusions In our model, remdesivir administration profoundly contributed to free hospital capacities in the metropolitan city Cologne in Germany.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Jeck, Julia UNSPECIFIED orcid.org/0000-0002-4669-690X UNSPECIFIED Jakobs, Florian UNSPECIFIED UNSPECIFIED UNSPECIFIED Kron, Anna UNSPECIFIED UNSPECIFIED UNSPECIFIED Cornely, Oliver A. UNSPECIFIED orcid.org/0000-0001-9599-3137 UNSPECIFIED Kron, Florian UNSPECIFIED orcid.org/0000-0003-4907-7490 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-669643
DOI:	10.1093/jac/dkab432
Journal or Publication Title:	J. Antimicrob. Chemother.
Volume:	77
Number:	3
Page Range:	S. 753 - 758
Date:	2022
Publisher:	OXFORD UNIV PRESS
Place of Publication:	OXFORD
ISSN:	1460-2091
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CORONAVIRUS Multiple languages Infectious Diseases; Microbiology; Pharmacology & Pharmacy Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/66964